Illumina, Inc. (NASDAQ:ILMN) has received a consensus rating of “Hold” from the twenty-three brokerages that are presently covering the company, MarketBeat reports. Three analysts have rated the stock with a sell recommendation, eight have assigned a hold recommendation and eleven have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $190.25.

ILMN has been the topic of a number of recent analyst reports. BidaskClub raised Illumina from a “sell” rating to a “hold” rating in a research note on Saturday, June 24th. Vetr raised Illumina from a “buy” rating to a “strong-buy” rating and set a $197.84 price target on the stock in a research note on Tuesday, June 27th. Morgan Stanley reaffirmed an “underweight” rating and set a $122.00 price target (up previously from $115.00) on shares of Illumina in a research note on Monday, July 10th. Barclays PLC reaffirmed a “hold” rating and set a $150.00 price target on shares of Illumina in a research note on Wednesday, July 19th. Finally, Canaccord Genuity reaffirmed a “hold” rating and set a $170.00 price target on shares of Illumina in a research note on Wednesday, July 26th.

In other Illumina news, SVP Charles Dadswell sold 1,609 shares of the stock in a transaction dated Thursday, August 3rd. The stock was sold at an average price of $197.00, for a total value of $316,973.00. Following the completion of the sale, the senior vice president now directly owns 9,037 shares in the company, valued at $1,780,289. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Jay T. Flatley sold 20,000 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was sold at an average price of $176.43, for a total value of $3,528,600.00. Following the completion of the sale, the director now owns 534,176 shares of the company’s stock, valued at $94,244,671.68. The disclosure for this sale can be found here. Insiders sold 182,766 shares of company stock valued at $36,411,334 over the last 90 days. Corporate insiders own 1.60% of the company’s stock.

Several hedge funds have recently bought and sold shares of the company. First Citizens Bank & Trust Co. boosted its position in shares of Illumina by 0.4% during the second quarter. First Citizens Bank & Trust Co. now owns 3,088 shares of the life sciences company’s stock worth $536,000 after buying an additional 12 shares during the period. Patten Group Inc. boosted its position in shares of Illumina by 2.7% during the first quarter. Patten Group Inc. now owns 965 shares of the life sciences company’s stock worth $166,000 after buying an additional 25 shares during the period. Puzo Michael J boosted its position in shares of Illumina by 0.4% during the second quarter. Puzo Michael J now owns 5,955 shares of the life sciences company’s stock worth $1,032,000 after buying an additional 25 shares during the period. Flagship Harbor Advisors LLC boosted its position in shares of Illumina by 1.7% during the second quarter. Flagship Harbor Advisors LLC now owns 2,046 shares of the life sciences company’s stock worth $345,000 after buying an additional 35 shares during the period. Finally, Eqis Capital Management Inc. boosted its position in shares of Illumina by 0.6% during the second quarter. Eqis Capital Management Inc. now owns 6,914 shares of the life sciences company’s stock worth $1,200,000 after buying an additional 38 shares during the period. 93.32% of the stock is owned by institutional investors.

WARNING: This report was originally posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally copied and reposted in violation of US and international trademark and copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/10/22/illumina-inc-ilmn-receives-190-25-consensus-pt-from-analysts.html.

Illumina (NASDAQ ILMN) traded up 2.29% on Thursday, reaching $209.88. The company had a trading volume of 727,020 shares. Illumina has a 12 month low of $119.37 and a 12 month high of $214.34. The company’s 50 day moving average price is $205.74 and its 200-day moving average price is $186.97. The company has a market capitalization of $30.64 billion, a price-to-earnings ratio of 42.11 and a beta of 0.76.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings data on Tuesday, August 1st. The life sciences company reported $0.82 EPS for the quarter, topping analysts’ consensus estimates of $0.68 by $0.14. The company had revenue of $662.00 million for the quarter, compared to analyst estimates of $642.38 million. Illumina had a return on equity of 19.69% and a net margin of 30.27%. The business’s revenue was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.86 earnings per share. On average, equities analysts predict that Illumina will post $3.65 earnings per share for the current fiscal year.

About Illumina

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Analyst Recommendations for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.